Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4⁺ T Cells of Patients with Relapsing-Remitting Multiple Sclerosis

Figure 4

TGFBR2 and miR-106b expression analysis. (a) Transcriptional expression of TGFBR2 was analyzed with real-time RT-PCR in freshly isolated CD4⁺ T cells from HVs transiently transfected by electroporation (EP) with 1 μM of miR-17 synthetic inhibitor (ImiR-17) or vehicle control (mock) (𝑛=7) (bars represent mean with SEM) and (b) in CD4⁺ T cells from HVs and untreated and natalizumab treated patients (𝑛=14). (c) Analysis of transcriptional expression of miR-106b in CD4⁺ T cells from HVs and untreated and natalizumab treated patients (𝑛=14). Bars represent median with interquartile range. Relative expression levels are depicted. One-way ANOVA with Tukey’s multiple comparison test was applied.^∗∗∗𝑃<0.001,^∗∗𝑃<0.01;^∗𝑃<0.05; n.s.: not significant.

(a)

(b)

(c)